Acta Scientific ANATOMY

Volume 2 Issue 6 September 2023

Short Communication

Pathophysiology of Neurodegenerative Diseases; Alzheimer's Disease, Parkinson's Disease, and Amyotrophic Lateral Sclerosis (ALS)

EMMANSON EG*

Department of Human Anatomy, Cross River University of Technology, Nigeria

***Corresponding Author:** EMMANSON EG, Department of Human Anatomy, Cross River University of Technology, Nigeria

Received: September 12, 2023

Published: September 26, 2023

Neurodegenerative diseases are a group of disorders that affect the structure and function of neurons, the cells that transmit information in the brain and nervous system. These diseases cause progressive loss of cognitive, motor, and sensory abilities, leading to disability and death. Some of the most common neurodegenerative diseases are Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS).

The causes and mechanisms of neurodegeneration are not fully understood, but research has identified some common factors that contribute to the onset and progression of these diseases. These include

- **Protein Aggregation:** Many neurodegenerative diseases are associated with the accumulation of abnormal or misfolded proteins in the brain, which can form toxic aggregates or clumps that impair the normal function and survival of neurons. For example, AD is characterized by the deposition of amyloid-beta plaques and tau tangles [1], Parkinson's Disease by the formation of alpha-synuclein Lewy bodies, and ALS by the aggregation of TDP-43 or SOD1 [2].
- **Mitochondrial Dysfunction:** Mitochondria are the organelles that produce energy for the cells, and they are especially important for neurons, which have high metabolic demands. Mitochondrial dysfunction can result from genetic mutations, oxidative stress, or environmental toxins, and it can lead to energy deficiency, impaired calcium homeostasis, and increased production of reactive oxygen species (ROS), which can damage cellular components [4]. Mitochondrial dysfunction has been implicated in AD [1], PD, and ALS.
- **Oxidative Stress**: Oxidative stress is a condition where there is an imbalance between the production and elimination of ROS, which are molecules that can react with and damage DNA, proteins, lipids, and other cellular components. Oxidative stress can result from mitochondrial dysfunction, inflammation, or exposure to environmental toxins, and it can trigger a vicious cycle of cellular damage and impaired antioxidant defense[4]. Oxidative stress has been observed in AD[1], PD, and ALS [3-7].
- **Neuroinflammation**: Neuroinflammation is the response of the immune system to injury or infection in the brain, which involves the activation of microglia (the resident immune cells of the brain) and astrocytes (the supportive cells of the brain), as well as the release of cytokines (chemical messengers that regulate inflammation). Neuroinflammation can be beneficial in removing pathogens and debris, but it can also become chronic and harmful, causing neuronal damage and death. Neuroinflammation has been linked to AD [1]. PD and ALS [2].
- **Excitotoxicity**: Excitotoxicity is a phenomenon where excessive stimulation of neurons by glutamate (the main excitatory neurotransmitter in the brain) leads to calcium overload, mitochondrial dysfunction, oxidative stress, and neuronal death. Excitotoxicity can result from impaired glutamate uptake or clearance, increased glutamate release, or altered glutamate receptor expression or function. Excitotoxicity has been implicated in AD [1]. PD, and ALS.

Understanding the pathophysiology of neurodegenerative diseases is crucial for developing potential therapeutic strategies that can prevent or slow down the disease progression. Some of these strategies include

- **Modulating Protein Aggregation**: Several approaches have been proposed to reduce or eliminate the toxic protein aggregates in neurodegenerative diseases, such as enhancing their degradation by autophagy (a cellular process that recycles damaged or unwanted components) or proteasomes (a complex that breaks down proteins), inhibiting their formation by

stabilizing their native structure or blocking their aggregation sites, or neutralizing their effects by using antibodies or small molecules that bind to them.

- **Enhancing Mitochondrial Function**: Various strategies have been suggested to improve mitochondrial function in neurodegenerative diseases, such as boosting their biogenesis (the process of creating new mitochondria), increasing their antioxidant capacity (the ability to scavenge ROS), restoring their membrane potential (the voltage difference across their membrane), or protecting them from damage by using mitochondrial-targeted antioxidants or peptides.
- **Reducing Oxidative Stress**: Several antioxidants have been tested as potential therapies for neurodegenerative diseases, such as vitamin E, vitamin C, coenzyme Q10, N-acetylcysteine, alpha-lipoic acid, melatonin, curcumin, resveratrol, and polyphenols. These antioxidants can either directly scavenge ROS or enhance the endogenous antioxidant defense system by activating transcription factors such as Nrf2 (nuclear factor erythroid 2-related factor 2) or enzymes such as superoxide dismutase (SOD), catalase (CAT), or glutathione peroxidase (GPx).
- **Attenuating Neuroinflammation***:* Several anti-inflammatory agents have been explored as potential treatments for neurodegenerative diseases, such as non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, cyclooxygenase-2 (COX-2) inhibitors, cytokine inhibitors, or immunomodulators. These agents can either inhibit the activation of microglia and astrocytes or suppress the production or action of pro-inflammatory cytokines.
- **Preventing Excitotoxicity**: Several drugs have been developed to modulate glutamate signaling and prevent excitotoxicity in neurodegenerative diseases, such as NMDA receptor antagonists, AMPA receptor antagonists, metabotropic glutamate receptor agonists or antagonists, glutamate transporter activators or inhibitors, or glutamate synthesis inhibitors. These drugs can either reduce the amount of glutamate available for neuronal stimulation or decrease the sensitivity of neurons to glutamate.

Neurodegenerative diseases are complex and multifactorial disorders that involve various molecular and cellular mechanisms that interact and influence each other. Therefore, a comprehensive and integrative approach that targets multiple pathways and factors is likely to be more effective than a single-targeted therapy. Moreover, early diagnosis and intervention are essential for maximizing the therapeutic outcomes and improving the quality of life of patients and caregivers.

Bibliography

1. Neurodegenerative Diseases: Symptoms and Treatment - Verywell Mind.
2. Pathophysiology of Neurodegenerative Diseases: Basics to Advanced.
3. https://www.technologynetworks.com/neuroscience/articles/pathophysiology-of
4. Frontiers | Neurodegenerative Diseases – Is Metabolic Deficiency the.
5. https://jcp.bmj.com/content/72/11/725
6. https://en.wikipedia.org/wiki/Neurodegenerative_disease.
7. https://my.clevelandclinic.org/health/diseases/24976-neurodegenerative-diseases.